First Allied Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

First Allied Advisory Services’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$50K	Sell	17,000 -14,000	-45%	-$54.7K	﹤0.01%	1165
2020 Q2	$143K	Hold	31,000	–	–	0.01%	1045
2020 Q1	$119K	Buy	31,000 +2,000	+7%	+$8.21K	0.01%	991
2019 Q4	$109K	Hold	29,000	–	–	﹤0.01%	1170
2019 Q3	$154K	Hold	29,000	–	–	0.01%	1155
2019 Q2	$111K	Buy	29,000 +2,000	+7%	+$8.64K	﹤0.01%	1157
2019 Q1	$138K	Hold	27,000	–	–	﹤0.01%	1094
2018 Q4	$52K	Buy	27,000 +1,000	+4%	+$2.86K	﹤0.01%	1045
2018 Q3	$98K	Hold	26,000	–	–	﹤0.01%	1147
2018 Q2	$81K	Hold	26,000	–	–	﹤0.01%	1120
2018 Q1	$62K	Hold	26,000	–	–	﹤0.01%	1144
2017 Q4	$102K	Hold	26,000	–	–	﹤0.01%	1198
2017 Q3	$66K	Hold	26,000	–	–	﹤0.01%	1100
2017 Q2	$72K	Buy	+26,000	New	+$54.3K	﹤0.01%	1113

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

First Allied Advisory Services's CPRX Position: Q3 2020 in Review

First Allied Advisory Services reduced its Catalyst Pharmaceutical (CPRX) stake by 45% in Q3 2020, selling an estimated $54.7K and leaving 17,000 shares worth $50K. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

First Allied Advisory Services first reported a position in CPRX in Q2 2017 and has held it in 14 quarters since. The position peaked at $154K in Q3 2019. 142 funds tracked by Wall St. Rank hold CPRX as of Q3 2020.

First Allied Advisory Services held 17,000 shares of Catalyst Pharmaceutical worth $50K as of Q3 2020.
First Allied Advisory Services sold 14,000 Catalyst Pharmaceutical shares in Q3 2020, an estimated $54.7K.
Catalyst Pharmaceutical made up ﹤0.01% of First Allied Advisory Services's portfolio in Q3 2020, its #1165 holding.
First Allied Advisory Services first reported a position in Catalyst Pharmaceutical in Q2 2017 and has held it in 14 quarters since.
First Allied Advisory Services's Catalyst Pharmaceutical position peaked at $154K in Q3 2019.
142 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.